----- Original Message -----

From: Art Hansen

To: LDN_Users@yahoogroups.com

Sent: Friday, March 02, 2007 7:06 AM

Subject: [LDN_Users] Re: RELIV

--- In LDN_Users@yahoogroups.com, "tbayuk" <tbayuk@...> wrote:
>
> Hi Folks,
> The proper spelling of the product that I asked about is;
>
> ....RELIV....
>
> Thanks in advance.
> Regards,
> Tom
>

Is this what you're asking about?

Accentia Biopharmaceuticals Acquires Worldwide Exclusive License to
Revimmune for All Autoimmune Diseases
28 Feb 2007
Revimmune uses an approved drug in a new patent-pending method to
eliminate autoimmunity: In clinical studies for the lead indication
of multiple sclerosis (MS), Revimmune improves function in most
patients and stops progression in over 90% of cases refractory to
standard therapies; Licensed technology applicable to 80 autoimmune
diseases: long-term follow-up in severe, refractory, life-threatening
autoimmune aplastic anemia demonstrates 70% of patients maintain
complete remissions

TAMPA, FL, USA | Feb 28, 2007 | Accentia Biopharmaceuticals, Inc.
(NASDAQ: ABPI) has acquired the exclusive worldwide rights for
Revimmune(TM), a patent-pending pharmaceutical treatment in late-
stage development for a variety of autoimmune diseases. The in-
license advances the Company's strategy of acquiring late stage drug
candidates that can benefit from the 505(b)(2) regulatory pathway.
Revimmune uses an ultra-high intensity, short-course of an
intravenous formulation of an approved drug (cyclophosphamide), in a
new patent-pending method to "reboot" a patient's immune system,
thereby eliminating the autoimmunity, whereas current therapies
including oral cyclophosphamide are used chronically to try to
suppress the inflammation of autoimmunity. Based on long-term follow-
up showing complete remissions, there is substantial evidence that
Revimmune has the potential to cure cases of severe refractory
autoimmune diseases such as aplastic anemia and myasthenia gravis.
Accentia's lead indication or Revimmune is multiple sclerosis (MS).